AstraZeneca PLC AZN
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 16.21B | 15.38B | 15.29B | 15.50B | 15.19B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.21B | 15.38B | 15.29B | 15.50B | 15.19B |
| Cost of Revenue | 2.93B | 2.53B | 2.67B | 3.17B | 2.80B |
| Gross Profit | 13.28B | 12.85B | 12.62B | 12.33B | 12.39B |
| SG&A Expenses | 5.11B | 5.72B | 5.03B | 5.32B | 5.23B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -276.00M | -152.00M | -155.00M | 53.00M | -89.00M |
| Total Operating Expenses | 11.42B | 11.78B | 11.02B | 12.16B | 11.61B |
| Operating Income | 4.79B | 3.61B | 4.27B | 3.35B | 3.58B |
| Income Before Tax | 3.96B | 2.80B | 3.91B | 2.63B | 3.24B |
| Income Tax Expenses | 842.00M | 291.00M | 833.00M | 300.00M | 709.00M |
| Earnings from Continuing Operations | 3.12B | 2.51B | 3.08B | 2.33B | 2.54B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 1.00M | -1.00M | -1.00M | -3.00M | -2.00M |
| Net Income | 3.12B | 2.51B | 3.08B | 2.33B | 2.53B |
| EBIT | 4.79B | 3.61B | 4.27B | 3.35B | 3.58B |
| EBITDA | 6.26B | 5.19B | 5.64B | 4.11B | 5.13B |
| EPS Basic | 2.01 | 1.62 | 1.99 | 1.50 | 1.63 |
| Normalized Basic EPS | 1.76 | 1.31 | 1.59 | 1.23 | 1.31 |
| EPS Diluted | 2.00 | 1.61 | 1.97 | 1.48 | 1.62 |
| Normalized Diluted EPS | 1.75 | 1.30 | 1.58 | 1.22 | 1.30 |
| Average Basic Shares Outstanding | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B |
| Average Diluted Shares Outstanding | 1.56B | 1.56B | 1.56B | 1.56B | 1.56B |
| Dividend Per Share | 0.00 | 1.06 | -- | 2.17 | 0.00 |
| Payout Ratio | 53.48% | 0.04% | 106.72% | -- | 63.60% |